TW202010500A - 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物 - Google Patents

作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物 Download PDF

Info

Publication number
TW202010500A
TW202010500A TW108112189A TW108112189A TW202010500A TW 202010500 A TW202010500 A TW 202010500A TW 108112189 A TW108112189 A TW 108112189A TW 108112189 A TW108112189 A TW 108112189A TW 202010500 A TW202010500 A TW 202010500A
Authority
TW
Taiwan
Prior art keywords
mmol
alkyl
group
methyl
amino
Prior art date
Application number
TW108112189A
Other languages
English (en)
Chinese (zh)
Inventor
張國良
昌友 周
Original Assignee
開曼群島商百濟神州有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 開曼群島商百濟神州有限公司 filed Critical 開曼群島商百濟神州有限公司
Publication of TW202010500A publication Critical patent/TW202010500A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW108112189A 2018-04-08 2019-04-08 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物 TW202010500A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2018/082140 2018-04-08
CN2018082140 2018-04-08

Publications (1)

Publication Number Publication Date
TW202010500A true TW202010500A (zh) 2020-03-16

Family

ID=68163465

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108112189A TW202010500A (zh) 2018-04-08 2019-04-08 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物

Country Status (15)

Country Link
US (1) US11472811B2 (enExample)
EP (1) EP3774813A4 (enExample)
JP (1) JP2021520392A (enExample)
KR (1) KR20200140849A (enExample)
CN (1) CN112313234B (enExample)
AU (1) AU2019251148A1 (enExample)
BR (1) BR112020020078A2 (enExample)
CA (1) CA3095839A1 (enExample)
EA (1) EA202092036A1 (enExample)
IL (1) IL277744A (enExample)
MX (1) MX2020010618A (enExample)
SG (1) SG11202009706VA (enExample)
TW (1) TW202010500A (enExample)
WO (1) WO2019196803A1 (enExample)
ZA (1) ZA202005772B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200140849A (ko) 2018-04-08 2020-12-16 베이진 엘티디 A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체
WO2021191376A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
US12552799B2 (en) 2020-03-26 2026-02-17 Nxera Pharma Uk Limited Triazolone compounds
WO2022087146A1 (en) 2020-10-22 2022-04-28 Landos Biopharma, Inc. Lancl ligands
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
BR0213172A (pt) 2001-10-08 2004-09-14 Hoffmann La Roche Amida do ácido 8-amino-[1,2,4]triazolo[1,5-a]piridina-6-carboxìlico
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
CN103261202B (zh) 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
KR20200140849A (ko) 2018-04-08 2020-12-16 베이진 엘티디 A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체
CN110742893B (zh) 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法

Also Published As

Publication number Publication date
BR112020020078A2 (pt) 2021-01-05
WO2019196803A1 (en) 2019-10-17
SG11202009706VA (en) 2020-10-29
CN112313234A (zh) 2021-02-02
EA202092036A1 (ru) 2021-01-28
ZA202005772B (en) 2022-01-26
US20210198267A1 (en) 2021-07-01
IL277744A (en) 2020-11-30
US11472811B2 (en) 2022-10-18
AU2019251148A1 (en) 2020-10-22
CA3095839A1 (en) 2019-10-17
MX2020010618A (es) 2020-11-12
JP2021520392A (ja) 2021-08-19
CN112313234B (zh) 2022-04-29
EP3774813A1 (en) 2021-02-17
EP3774813A4 (en) 2021-11-17
KR20200140849A (ko) 2020-12-16

Similar Documents

Publication Publication Date Title
CN114341127B (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
CN114585359B (zh) 用于治疗pd-l1疾病的杂芳基联苯酰胺
CN114555080B (zh) 用于治疗pd-l1疾病的杂芳基联苯胺
KR101879422B1 (ko) Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물
US12187742B2 (en) Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy
TW202110843A (zh) 含氮雜環類衍生物調節劑、其製備方法和應用
TWI672304B (zh) 作爲酪胺酸激酶抑制劑之經取代的乙炔基雜雙環化合物
JP7847123B2 (ja) 化合物、組成物及び方法
TW201726623A (zh) 作為免疫調節劑之雜環化合物
US11472811B2 (en) Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
TWI762534B (zh) 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物
US20260078103A1 (en) Isoquinolones as pi3k inhibitors
CN110742893B (zh) A2a受体拮抗剂治疗癌症的方法
TW202028209A (zh) 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
US20240327417A1 (en) Heterocyclic compounds
US20260125346A1 (en) Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease
JP2025516213A (ja) サイクリン依存性キナーゼ阻害剤としての置換6-(ピリミジン-4-イル)キノリン化合物
JP2021506876A (ja) PDE1阻害剤としてのピラゾロ[3,4−b]ピリジン及びイミダゾ[1,5−b]ピリダジン
CN116249692B (zh) 吡唑类化合物及其制备方法和用途
TW202024072A (zh) 作為PI3Kβ抑制劑的1,5-二氮雜萘-4(1H)-酮衍生物
HK40036174A (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
TW202225162A (zh) 芳香雜環類化合物、藥物組合物及其應用
BR112019010617B1 (pt) Composto de oxoisoquinolina, seu uso e composição farmacêutica que o compreende